HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

New Pharmacotherapy Targeting Cognitive Dysfunction of Schizophrenia via Modulation of GABA Neuronal Function.

Abstract
Schizophrenia is considered a neurodevelopmental and neurodegenerative disorder. Cognitive impairment is a core symptom in patients with the illness, and has been suggested a major predictor of functional outcomes. Reduction of parvalbumin (PV)-positive γ-aminobutyric acid (GABA) interneurons has been associated with the pathophysiology of schizophrenia, in view of the link between the abnormality of GABA neurons and cognitive impairments of the disease. It is assumed that an imbalance of excitatory and inhibitory (E-I) activity induced by low activity of glutamatergic projections and PV-positive GABA interneurons in the prefrontal cortex resulted in sustained neural firing and gamma oscillation, leading to impaired cognitive function. Therefore, it is important to develop novel pharmacotherapy targeting GABA neurons and their activities. Clinical evidence suggests serotonin (5-HT) 1A receptor agonist improves cognitive disturbances of schizophrenia, consistent with results from preclinical studies, through mechanism that corrects E-I imbalance via the suppression of GABA neural function. On the other hand, T-817MA, a novel neurotrophic agent, ameliorated loss of PV-positive GABA neurons in the medial prefrontal cortex and reduction of gamma-band activity, as well as cognitive dysfunction in animal model of schizophrenia. In conclusion, a pharmacotherapy to alleviate abnormalities in GABA neurons through 5-HT1A agonists and T-817MA is expected to prevent the onset and/or progression of schizophrenia.
AuthorsTakashi Uehara, Tomiki Sumiyoshi, Masayoshi Kurachi
JournalCurrent neuropharmacology (Curr Neuropharmacol) Vol. 13 Issue 6 Pg. 793-801 ( 2015) ISSN: 1875-6190 [Electronic] United Arab Emirates
PMID26630957 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
Chemical References
  • Psychotropic Drugs
  • Receptor, Serotonin, 5-HT1A
  • gamma-Aminobutyric Acid
Topics
  • Animals
  • Cognition Disorders (complications, drug therapy, metabolism)
  • Humans
  • Psychotropic Drugs (pharmacology, therapeutic use)
  • Receptor, Serotonin, 5-HT1A (metabolism)
  • Schizophrenia (complications, drug therapy, metabolism)
  • Schizophrenic Psychology
  • gamma-Aminobutyric Acid (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: